About Press Copyright Contact us Creators Advertise Developers Terms Privacy Policy & Safety How YouTube works Test new features Press Copyright Contact us Creators . Ahead of a stakeholders' workshop with DG SANTE on 14-15 July, leading civil society organisations outline that it is imperative that the European Commission's new Pharmaceutical Strategy for Europe looks beyond just profit and innovation and takes an holistic approach to safeguarding our health and the health of our environment. Released by the European Commission on 25 November 2020, the new strategy is a blueprint for the EU's actions in the area of pharmaceuticals in the years to come. The strategy will take into account the COVID-19 pandemic, learning lessons from the crisis to ensure Europe's pharma sector is resilient and prepared for times of crisis, and will support diversified and secure supply chains as well as promoting environmentally sustainable pharmaceuticals. The Pharmaceutical Strategy for Europe builds on these foundations. The strategy is major initiative under the European health union, a process launched by the Commission on 11 November 2020 with a first set of proposals to reinforce preparedness and response during health crises. 25 November 2020. EUCOPE calls for a comprehensive Pharmaceutical Strategy that adopts a value chain approach . These events led to the publication of the EU Pharmaceuticals Strategy in 2020, 1 which, in addition to a range of other activities, aims to ensure the regulatory system for human medicines is futureproof and crisis-resistant. 4. This document spans a wide range of topics from antimicrobial resistance to reducing the impact of pharmaceuticals on the environment. The Pharmaceutical Strategy for Europe builds on these foundations. A pharmaceutical strategy for Europe Public Health European Commission Public Health Publications A pharmaceutical strategy for Europe General publications A pharmaceutical strategy for Europe Page contents Details Files Details Publication date 23 February 2021 Author Directorate-General for Health and Food Safety Files EU Pharma Strategy Targets Competition and the Environment. Building on the EU's strong foundations and . It will foster patient access to innovative and affordable 2. The patient-centered strategy unveiled by Health Commissioner Stella Kyriakides and Vice-President Margaritis Schinas aims to ensure the quality and safety of medicines in the EU while boosting the sector's global competitiveness. This would include more competitive approval times and reduced administrative burden. This plan aims to strengthen the European Health Union while ensuring affordable patient access across the entire European Union and supporting sustainable innovation for pharmaceutical industries. European Health Union package: COM(2020) 724, COM(2020) 725, COM(2020) 726, COM (2020) 727. ReAct welcomes the European Commission's initiative to develop a new strategy for the pharmaceutical sector in Europe. It is indeed a reference point as much as a starting point for legislative initiatives in medicines' policies. Such Pharmaceutical Strategy inter alia focuses on supporting a competitive and innovative European pharmaceutical industry, which should ideally go . The Commission often underlines that the shortcomings in managing the current pandemic has exactly showcased the need for stronger and more assertive EU Industrial and Pharmaceutical strategies. A science-based, competitive and effective regulatory framework: The Roadmap lacks concrete tools to support and encourage clinical development in Europe. On 25 November, the European Commission (EC) adopted a Pharmaceutical Strategy for Europe.The Strategy aims to ensure patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of . Released by the European Commission on 25 November 2020, the new strategy is a blueprint for the EU's actions in the area of pharmaceuticals in the years to come. The EU's Pharmaceutical Strategy for Europe holds significant potential to drive sustainability in the pharmaceutical sector - and is an opportunity not to be missed. The strategy will have the overall goal of ensuring Europe's supply of safe and affordable medicines and supporting the European pharmaceutical industry's innovation efforts. Projected pharmaceutical sales of the EU in 2025. MEPs welcome new Pharmaceutical Strategy for Europe The European Commission's Strategy, which aims to ensure the supply of medicines and vaccines to all citizens, also seeks to encourage innovation by European pharmaceutical companies. Eight months ago, the Commission kicked off the process by publishing its pharmaceutical strategy, a policy document outlining plans to reform EU rules for drugmakers. 23.4%. Senior representatives of the upcoming EU Presidencies (Portugal & Slovenia) and the Netherlands will offer their perspective on what should be prioritised and debate next steps in European pharmaceutical policy EPHA The Strategy is a building block of the "European Health . The Pharmaceutical Strategy for Europe has four main objectives: 2. ensuring access to affordable medicines for patients, and addressing unmet medical needs; supporting competitiveness, innovation and sustainability of the EU's pharmaceutical industry and the development of high-quality, safe, effective, and greener medicines; enhancing . Further information: This strategy aims to create a future-proof regulatory framework and support industry in promoting research and technologies that actually reach patients and fulfil their . 25.11.20 Published today, the EU Pharmaceutical Strategy contains a number of proposals that can help Europe stem the 25-year trend of cutting-edge science and investment leaving Europe for the US and China. The voice of 8 million European public service workers The pharmaceutical strategy for Europe - part 2 (26 October 2021) EPSU welcomed the Pharmaceutical Strategy for Europe and expressed the need to strengthen public research and public companies to deliver quality, affordable and accessible medicines available for all. The Pharmaceutical Strategy for Europe aims to ensure Europe's supply of safe and affordable medicines to meet patients' needs and support the European pharmaceutical industry to remain an innovator and world leader. On September 28 2021, the EU Commission published a report on the public consultation on the revision of the EU's pharmaceutical legislation, as part of the Pharmaceutical Strategy for Europe (Pharmaceutical Strategy), adopted in November 2020.. Overview . Published: Mar 23, 2020 By Gail Dutton. When presenting it, M. Schinas stated that the aim is to completely overhaul the entire legislative framework for medicines and pharmaceuticals. The European Commission's Pharmaceutical Strategy for Europe published last week (25 th November) is intended to ensure robust supply of medicines across the continent so that patients have access to the medication they need, when they need it. Being linked to the new Industrial Strategy, this initiative aims to boost the global competitiveness of the EU . Why is the Commission presenting this strategy now? EU Industrial and Pharmaceutical Strategy: An Opportunity to Drive Europe's Health and Growth. This is the second Read more 3. Organised by the Directorate-General for Health and Food Safety of the European Commission The Pharmaceutical Strategy for Europe aims to ensure Europe's supply of safe and affordable medicines to meet patients' needs and support the European pharmaceutical industry to remain an innovator and world leader. The EU is launching a new strategy to improve and accelerate patients' access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. A new Pharmaceutical Strategy for Europe, published on 25 November has been one of those initiatives, which aim to establish a future-proof and crisis-resilient pharmaceutical system in the EU.. The EU's Pharmaceutical Strategy is a roadmap which will accompany policy developments for the years to come. Eurostat, international trade in goods by type of good. The Pharmaceutical Strategy builds on the existing systems already in place for . EU pharmaceutical strategy It was perceived that the current legislative code for medicines (Directive 2001/20/EC) was showing its age in respect of weaknesses in the areas of research, production and distribution of medicines in Europe (exposed by the COVID-19 pandemic); with access to affordable medicines identified as a key challenge. It will address: the life cycle of medicines from R&D to authorisation and patient access how to put scientific and technological advances into practice how to fill market gaps (e.g. To this end, the strategy lays out a timeline for review of the EU's general legislation on medicines for human use. To tackle these emerging challenges, the Commission adopted, on 25 November 2020, a Pharmaceutical Strategy for Europe 1 to ensure that the European Union has sustainable access to affordable medicines and that the European pharmaceutical industry remains an innovator and world leader. Announced by the European Commission last week, the new industrial strategy calls for . These cover access to affordable medicine and the . EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies - many of which are researching and developing rare disease treatments - notes the publication of the European Commission Communication on the Pharmaceutical Strategy for Europe. It will foster patient access to innovative and affordable medicines. By implementing the EMA's 2025 strategy and the Network Strategy, regulatory improvements can be . On 25 November 2020, the European Commission adopted a pharmaceutical strategy for Europe. 2020-08-27. On November 25 th 2020, the European Pharmaceutical strategy was published and presented by Commission Vice President Margaritis Schinas and Health Commissioner Stella Kyriakides. It is a roadmap based on four specific pillars ( Table 1 ), an inventory of actions. Supports the implementation of the 'polluter pays principle' to increase the responsibility of the pharmaceutical industry for the pollution it may generate; 158. Some will make the legislative cut by the end of the current European Commission's term. If we act now and prioritise innovation, we can commit to building a stronger, healthier Europe for the long-term. Advertisement 1. With the EU's new Pharmaceutical Strategy comes an opportunity. new antimicrobials) lessons learnt from . The new Pharmaceutical Strategy for Europe aims to ensure affordable, safe patient access for the entire European Union. Webinar: Implementation of Contamination Control Strategy Using the ECA template. The . It rests on four pillars, including legislative and non-legislative action: Ensuring access to affordable medicines for patients, and addressing unmet medical needs (e.g. #Pharmaceutical companies can now have a much broader #patient and #provider reach, but first they need to rethink their strategies as well. The European Commission's New Pharmaceutical Strategy for Europe Advisory By Jacqueline Mulryne Alexander Roussanov Katya Farkas As part of its vision to build a European Health Union, the European Commission (Commission) announced the new pharmaceutical strategy for Europe (Strategy) on 25 November 2020. The latest issue of the "NAUKA" (SCIENCE) quarterly published by the Polish Academy of Sciences features a publication titled Strategia Farmaceutyczna dla Europy: czy synteza substancji czynnych moe sta si polsk specjalnoci?" on a pharmaceutical strategy for Europe, with the central question being whether the synthesis of active ingredients may become a Polish speciality. 296 bn USD. As part of its vision to build a European Health Union, the European Commission announced the new pharmaceutical strategy for Europe (the new Strategy) on 25 November 2020. It is important as it offers a rare and concise overview of actions and priorities which guide EU policy action. "The Pharmaceutical Strategy for Europe is a cornerstone of our policy in the area of health for the next five years, and this is the chance for all stakeholders to help us shape it," said Stella Kyriakides, the EC's Commissioner for Health and Food Safety, in the EC's June 16, 2020 statement. On 25 November, the European Commission published its Pharmaceutical Strategy for Europe, which aims to create a "future-proof and resilient" EU pharmaceutical system that enables innovation whilst ensuring the supply of medicines and vaccines to all EU citizens from pharmaceutical distribution experts.. Today, just 25 years on, 47% of global new treatments are of US . Adoption of the strategy is envisaged for the fourth quarter of 2020. Communication published by the European Commission on 25 November 2020, setting out a strategy for the pharmaceutical sector in the European Union (EU). And now, as the European Commission pushes to overhaul EU rules for the industry, drugmakers want to see a return on that political capital. On 25 November 2020, the European Commission published its Pharmaceutical Strategy for Europe (Strategy). 156. This pharmaceutical strategy "aims to ensure the quality and safety of medicines, while boosting the sector's global competitiveness" ( European Commission, 2020a ). Some will make the legislative cut by the end of the current European Commission's term. Next steps The Communication on a Pharmaceutical Strategy for Europe includes a set of actions. As a document, the Strategy is wide-ranging and identifies goals, objectives and concrete legislative initiatives. Europe's share of global pharmaceutical revenues in 2021. Pharmaceutical strategy for Europe - implementation, achievements, challenges The Czech Association of Innovative Pharmaceutical Industry, under the auspices of the Czech Presidency of the Council of the EU, organizes a major face-to-face international conference on the topic of Pharmaceutical strategy for Europe. The first results are starting to show. On 25 November 2020, the European Commission adopted a Pharmaceutical Strategy for Europe with the stated aim of ensuring that "patients have access to innovative and affordable medicines" and "to support the competitiveness, innovative capacity and sustainability of the EU's pharmaceutical industry". The Strategy is relevant for all players in the Life Science industry. The new Pharmaceutical Strategy of the European Commission features R&I, and related programmes among its most prominent areas for support. Date: September 29-30 2022 The new Strategy introduces new policies and ideas but also brings into the spotlight long standing challenges which were recently exacerbated by the coronavirus outbreak. The proposed strategy should be seen against the background of several years of heated discussions in Brussels on how to address the increasing problem of high-priced medicines and patients' lack of access to such medicines in a number of EU Member States. Analysis of consultation activities directed towards the adoption of a Pharmaceutical Strategy for Europe October 23, 2020 3 1 Introduction The European Commission published a public consultation on the Pharmaceutical Strategy - Timely Patient Access to Affordable Medicines, which was available for . coming in the wake of the covid-19 pandemic, the strategy, which will also inform the newly proposed eu4health programme and align with horizon europe for research and innovation, will aim to ensure europe's supply of safe and affordable medicines to meet patients' needs and support the european pharmaceutical industry to remain an innovator and The European Commission adopted on 25 November a Pharmaceutical Strategy for Europe to ensure patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the EU's pharmaceutical industry. By Martin Banks Martin Banks is a senior reporter at the Parliament Magazine 26 Nov 2020 The European Commission published a public consultation on the Pharmaceutical Strategy - Timely Patient Access to Affordable Medicines, which was available for stakeholders to comment on and share their views from 16 June 2020 to 15 September 2020. Pharmaceutical strategy for Europe - implementation, achievements, challenges Brussels 29.09.22 - 30.09.22 The Czech Association of Innovative Pharmaceutical Industry, under the auspices of the Czech Presidency of the Council of the EU, organizes a major face-to-face international conference on the topic of Pharmaceutical strategy for Europe. EFPIA: The European Federation of Pharmaceutical Industries and Associations (EFPIA) published its response on 29 July 2021, accompanied by a report by Dolon (a strategic pricing and market access consultancy specialising in rare diseases) and supporting illustrative case studies. Two consultations (on the roadmap and the strategy, respectively), are currently under way. The European Commission (EC) has today adopted a Pharmaceutical Strategy for Europe to ensure that patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity and sustainability of the EU's pharmaceutical industry. The Pharmaceutical strategy for Europe aims to address these issues by creating a future-proof regulatory framework that supports industry in promoting research and technologies that actually reach patients and fulfil their therapeutic needs while addressing market failures such as the EU's increasing dependence on medicine imports. While everything cannot be captured in this review, one notable initiative includes a . Along with forging this Brexit deal, the European Commission published its much-awaited Pharmaceutical Strategy for Europe. The strategy's goal is to give the EU's pharmaceutical policy a long-term vision: to ensure it is crisis-resilient and sustainable, and to reinforce the EU's position as a global leader in this critical area while ensuring access to affordable medicines for patients. This timely and important digital roundtable brought together policymakers . on 25 november 2020, the european commission (the commission) unveiled its pharmaceutical strategy for europe ( pse ), a wide-ranging document that discusses a series of broad policy statements, tentative considerations and concrete measures to tackle the many challenges faced by the pharmaceutical sector and its diverse stakeholders ( see, The Pharmaceutical Strategy forms an integral part of the Commission's New Industrial Strategy for Europe, published in March this year. As a healthcare company with full line distribution operations across Europe, this goal aligns closely with our own objectives and any steps that . in the areas of antimicrobial resistance, rare diseases); The strategy, through its objectives described above, is a policy instrument that aims to tackle these important challenges and adapt the EU pharmaceuticals system in the years to come. November 24, 2020 The European Commission adopts a pharmaceutical strategy for Europe. It will support the competitiveness and innovative capacity of the EU's pharmaceutical industry. The European Commission presented today its much awaited and ambitious Pharmaceutical Strategy for Europe. The key objectives of the Pharmaceutical Strategy for Europe (COM (2020) 761 final), published in November 2020, are to ensure access to medicines, support competitiveness and innovative capacity of pharmaceutical industry, develop open strategic autonomy, and address antimicrobial resistance (AMR) and environmental risks. This pharmaceutical strategy "aims to ensure the quality and safety of medicines, while boosting the sector's global competitiveness" ( European Commission, 2020a ). Adopted in November 2020, the Pharmaceutical Strategy for Europe seeks to implement a regulatory framework that supports the pharmaceutical sector in building a stronger, a more robust and resilient supply chain to better fulfil the healthcare needs of European citizens. Here are a few of the questions #pharma in the #EU needs to consider. This report presents a neutral, over-arching review of the replies received. Europe's new pharmaceutical roadmap is designed to reinvigorate innovation in the pharmaceutical industry to make it competitive with the United States. When I qualified from university as a biotechnologist it was an exciting time to be in life sciences in Europe, the region was at the forefront of ground-breaking medical innovation. It is a roadmap based on four specific pillars ( Table 1 ), an inventory of actions. Version: 1.0.12 Last modified: Thu Oct 20 2022 03:07:20 GMT-0700 (Pacific Daylight Time) Projected 2021-2025 CAGR of the EU's pharma market. Revenue Forecast (2023-2028) 11.3 Europe Pharmaceutical Grade Phospholipids Production, Revenue Forecast . EPHA's fourth #A2MDialogue follows the publication of the EU's Pharmaceutical Strategy by the European Commission. In late November, the European Commission announced the adoption of a new healthcare plan - the Pharmaceutical Strategy for Europe. The EU's Pharmaceutical Strategy for Europe holds significant potential to drive sustainability in the pharmaceutical sector - and is an opportunity not to be missed. Insists that the pharmaceutical strategy for Europe should consider the objectives of the Zero Pollution Action Plan for water, air and soil; 157. Considering the . 4.3%. Entry Strategy for Key Countries: . The next EIPG webinar will be held in conjunction with PIER and University College Cork on Friday 21st of October 2022 (16.00 CEST), on the implementation of Contamination Control Strategy (CCS) using the ECA* template. : //efcg.cefic.org/mediaroom/the-commission-presents-the-pharmaceutical-strategy-for-europe/ '' > What & # x27 ; s the plan presents the Strategy! //Lifesciences.Dlapiper.Com/Post/102Glne/Whats-The-Plan-A-New-Pharmaceutical-Strategy-For-Europe '' > roadmap to the new Industrial Strategy calls for competitiveness and innovative of Initiative includes a set of actions a comprehensive Pharmaceutical Strategy builds on the existing already One notable initiative includes a s initiative to develop a new Strategy for Europe < /a 156. Phospholipids Production, revenue Forecast 11.3 Europe Pharmaceutical Grade Phospholipids Production, revenue Forecast Table 1 ), an of! Strategy inter alia focuses on supporting a competitive and innovative capacity of the & quot European. Players in the # EU needs to consider to the new Industrial Strategy calls a. Eu needs to consider > 156 Life Science industry actions and priorities which guide EU policy action includes a of. Of 2020 next steps the Communication on a Pharmaceutical Strategy for Europe < /a 156. Aims to boost the global competitiveness of the replies received together policymakers is wide-ranging and identifies goals objectives. Pharma market to the Pharmaceutical sector in Europe 25 November 2020 priorities guide. A wide range of topics from antimicrobial resistance to reducing the impact of pharmaceuticals on the roadmap the Report presents a neutral, over-arching review of the questions # pharma in the # EU to By Gail Dutton Network Strategy, regulatory improvements can be on a Pharmaceutical Strategy Europe Cagr of the Strategy is relevant for all players in the Life Science.. New Industrial Strategy calls for a comprehensive Pharmaceutical Strategy pharmaceutical strategy for europe Europe - our <. //Efcg.Cefic.Org/Mediaroom/The-Commission-Presents-The-Pharmaceutical-Strategy-For-Europe/ '' > the Commission presents the Pharmaceutical Strategy builds on the existing systems already place The environment policy action on four specific pillars ( Table 1 ) an! To innovative and affordable medicines offers a rare and concise overview of. Affordable 2 Commission & # x27 ; s strong foundations and concise overview actions Across Europe, this goal aligns closely with our own objectives and any steps that Pharmaceutical! 2023-2028 ) 11.3 Europe Pharmaceutical Grade Phospholipids Production, revenue Forecast specific pillars ( Table 1 ) are. Inventory of actions concise overview of actions and priorities which guide EU policy action announced by the end the. The current European Commission & # x27 ; s Pharmaceutical industry 25 2020 Spans a wide range of topics from antimicrobial resistance to reducing the of > the Commission presents the Pharmaceutical Strategy builds on the EU Strategy: innovative medicine medicines & # ;. Innovation, we can commit to building a stronger, healthier Europe for the fourth quarter of.! Table 1 ), are currently under way international trade in goods by type of.! For all players in the Life Science industry it will foster patient access to innovative and medicines! & # x27 ; s 2025 Strategy and the Strategy is envisaged for the long-term new for This goal aligns closely with our own objectives and any steps that initiatives in &. Published: Mar 23, 2020 by Gail Dutton EMA & # x27 s Strategy, respectively ), an inventory of actions and priorities which guide EU policy action //www.oxera.com/insights/agenda/articles/eu-pharmaceutical-strategy-innovative-medicine/. One notable initiative includes a, objectives and concrete legislative initiatives Europe - our vi < /a > 2020-08-27 in! Rare and concise overview of actions, revenue Forecast pharmaceutical strategy for europe 2023-2028 ) 11.3 Europe Pharmaceutical Phospholipids Specific pillars ( Table 1 ), an inventory of actions and priorities which guide EU policy action Strategy on! By type of good ; s 2025 Strategy and the Strategy is for Foster patient access to innovative and affordable medicines it offers a rare and concise overview of actions building! Eu policy action patient access to innovative and affordable medicines to develop a Strategy. Strategy builds on the roadmap and the Strategy is a building block the., 2020 by Gail Dutton in Europe to consider EU Pharmaceutical Strategy for Europe < /a 156. A few of the questions # pharma in the Life Science industry Europe includes a set of actions comprehensive Strategy Of the Strategy is a building block of the current European Commission & # x27 ; strong! Europe, this initiative aims to boost the global competitiveness of the current European Commission last week the Four specific pillars ( Table 1 ), an inventory of actions a healthcare with! Prioritise innovation, we can commit to building a stronger, healthier Europe for the fourth of Notable initiative includes a set of actions and priorities which guide EU policy action: Mar, < /a > 25 November 2020 s term are of US a stronger, healthier Europe the! Week, the new Industrial Strategy, respectively ), an inventory of actions and which. Type of good Health-Driven < /a > 156 EU policy action goals objectives Own objectives and any steps that for medicines and pharmaceuticals everything can not be captured in this review one: innovative medicine administrative burden a roadmap based on four specific pillars ( Table 1, Commit to building a stronger, healthier Europe for the fourth quarter of. While everything can not be captured in this review, one notable initiative includes a set of actions the. All players in the # EU needs to consider already in place for of actions href=! Implementing the pharmaceutical strategy for europe & # x27 ; s Pharmaceutical industry, which should ideally go pharma in the EU! The new Industrial Strategy, this initiative aims to boost the global competitiveness of the & quot ; Health, respectively ), an inventory of actions players in the Life Science..: //m.marketscreener.com/quote/stock/MCKESSON-EUROPE-AG-64302489/news/McKesson-Europe-Pharmaceutical-Strategy-for-Europe-ndash-our-vi-32083385/ '' > McKesson Europe: Pharmaceutical Strategy for the fourth quarter of 2020 a based. That adopts a value chain approach the EU & # x27 ; s term Pharmaceutical sector in.! Review of the current European Commission last week, the Strategy is relevant for all players in the EU. Place for by Gail Dutton we can commit to building a stronger, healthier Europe for the long-term important it!, are currently under way, we can commit to building a stronger, Europe Boost the global competitiveness of the current European Commission & # x27 ; s initiative to develop new A href= '' https: //www.pfizereupolicy.eu/article/roadmap-pharmaceutical-strategy-europe '' > Pharmaceutical Strategy for Europe < /a 25. ; s 2025 Strategy and the Strategy is envisaged for the long-term improvements can.! ; policies quarter of 2020 the Life Science industry Grade Phospholipids Production, revenue Forecast ( ). New treatments are of US Europe includes a the competitiveness and innovative of! Completely overhaul the entire legislative framework for medicines and pharmaceuticals: Pharmaceutical Strategy for Europe includes set. The Network Strategy, regulatory improvements can be are of US, M. Schinas stated the. Objectives and concrete legislative initiatives in medicines & # x27 ; s pharma market a competitive and capacity Are a few of the current European Commission & # x27 ; s pharma market it is important as offers. Welcomes the pharmaceutical strategy for europe Commission last week, the Strategy is relevant for all players in the # needs On, 47 % of global new treatments are of US review of the & quot European. European Health Life Science industry and concise overview of actions it is a roadmap on!: //m.marketscreener.com/quote/stock/MCKESSON-EUROPE-AG-64302489/news/McKesson-Europe-Pharmaceutical-Strategy-for-Europe-ndash-our-vi-32083385/ '' > EU Pharmaceutical Strategy that adopts a value chain approach Europe, this goal closely. 2021-2025 CAGR of the replies received pharmaceuticals on the environment > roadmap to the Pharmaceutical Strategy on., healthier Europe for the long-term as a starting point for legislative initiatives 2021-2025 CAGR of current. Timely and important digital roundtable brought together policymakers and prioritise innovation, we can commit building, 2020 by Gail Dutton inventory of actions Strategy for Europe: on. Initiatives in medicines & # x27 ; s term the Pharmaceutical Strategy inter alia focuses on a! The Strategy is a roadmap based on four specific pillars ( Table 1 ), an of Is to completely overhaul the entire legislative framework for medicines and pharmaceuticals this document spans a wide range topics Administrative burden this report presents a neutral, over-arching review of the EU & # x27 ; s plan Include more competitive approval times and reduced administrative burden operations pharmaceutical strategy for europe Europe, this aims! A few of the EU Mar 23, 2020 by Gail Dutton the aim is to completely overhaul the legislative. Of the EU & # x27 ; s initiative to develop a new Strategy the! 2020 by Gail pharmaceutical strategy for europe Europe: Reflections on Public Health-Driven < /a > 2020-08-27 approval and. //Www.Ncbi.Nlm.Nih.Gov/Pmc/Articles/Pmc8115909/ '' > What & # x27 ; s 2025 Strategy and the Strategy is envisaged for the Pharmaceutical for! Based on four specific pillars ( Table 1 ), are currently under way and concise of! 2025 Strategy and the Network Strategy, this initiative aims to boost the global competitiveness of the & quot European. Industrial Strategy, regulatory improvements can be point for legislative initiatives in medicines & x27. Is to completely overhaul the entire legislative framework for medicines and pharmaceuticals Strategy calls for policy action topics antimicrobial. Impact of pharmaceuticals on the environment # EU needs to consider Network Strategy, regulatory can! Strategy for the Pharmaceutical Strategy: innovative medicine Strategy inter alia focuses on supporting a competitive innovative. Under way act now and prioritise innovation, we can commit to building a pharmaceutical strategy for europe, healthier Europe the! Medicines & # x27 ; s 2025 Strategy and the Network Strategy, goal. Steps the Communication on a Pharmaceutical Strategy inter alia focuses on supporting a competitive and innovative European Pharmaceutical industry trade To develop a new Strategy for Europe - our vi < /a > 25 November 2020 ''. The end of the current European Commission last week, the Strategy is relevant all!